JAC Advance Access originally published online on January 19, 2005
Journal of Antimicrobial Chemotherapy 2005 55(2):240-245; doi:10.1093/jac/dkh531
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.55 no.2 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections
1 University of Washington School of Medicine, and General Internal Medicine Clinic, VA Puget Sound Health Care System (S-111-GIMC), 1660 S. Columbian Way, Seattle, WA 98108-1597; 2 Cubist Pharmaceuticals, Inc, Lexington, MA, USA
* Corresponding author. Tel: +1-206-764-2551; Fax: +1-206-764-2849; Email: benjamin.lipsky{at}med.va.gov
Objectives:
The predominant pathogens causing diabetic foot infections are Gram-positive cocci, many of which are now resistant to commonly prescribed antibiotics. Daptomycin is a new agent that is active against most Gram-positive pathogens. To compare the effectiveness of daptomycin against semi-synthetic penicillins or vancomycin, we analysed the subset of diabetic patients with an infected ulcer enrolled in two randomized, controlled investigator-blind trials of patients with complicated skin and soft-tissue infections presumptively caused by Gram-positive organisms.
Patients and methods:
Patients with a diabetic ulcer infection were prospectively stratified to ensure they were equally represented in the treatment groups, then randomized to either daptomycin [4 mg/kg every 24 h intravenously (iv)] or a pre-selected comparator (vancomycin or a semi-synthetic penicillin) for 7–14 days.
Results:
Among 133 patients with a diabetic ulcer infection, 103 were clinically evaluable; 47 received daptomycin and 56 received a comparator. Most infections were monomicrobial, and Staphylococcus aureus was the predominant pathogen. Success rates for patients treated with daptomycin or the comparators were not statistically different for clinical (66% versus 70%, respectively; 95% CI, –14.4, 21.8) or microbiological (overall or by pathogen) outcomes. Both treatments were generally well tolerated, with most adverse events of mild to moderate severity.
Conclusions:
The clinical and microbiological efficacy and safety of daptomycin were similar to those of commonly used comparator antibiotics for treating infected diabetic foot ulcers caused by Gram-positive pathogens. Daptomycin should be considered for treating these infections, especially those caused by resistant Gram-positive pathogens.
Keywords: diabetic ulcers , foot infections , soft tissue infections , antibiotic resistance , Gram-positive infections
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Kim, L. A. Suecof, C. A. Sutherland, L. Gao, J. L. Kuti, and D. P. Nicolau In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers Antimicrob. Agents Chemother., November 1, 2008; 52(11): 3941 - 3946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Seaton Daptomycin: rationale and role in the management of skin and soft tissue infections J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii15 - iii23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Paladino, J. L. Sunderlin, M. H. Adelman, M. E. Singer, and J. J. Schentag Observations on vancomycin use in U.S. hospitals Am. J. Health Syst. Pharm., August 1, 2007; 64(15): 1633 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Lipsky, P. Giordano, S. Choudhri, and J. Song Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate J. Antimicrob. Chemother., August 1, 2007; 60(2): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Credito, G. Lin, and P. C. Appelbaum Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill Methodology Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1504 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Jevitt, G. M. Thorne, M. M. Traczewski, R. N. Jones, J. E. McGowan Jr., F. C. Tenover, and S. D. Brown Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates. J. Clin. Microbiol., September 1, 2006; 44(9): 3098 - 3104. [Abstract] [Full Text] [PDF]
|
|